Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Buonaguro, L.; Tagliamonte, M.; Tornesello, M.L.; Buonaguro, F.M.
    SARS-CoV-2 RNA polymerase as target for antiviral therapy (2020), J. Transl. Med., 18, 185 .
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.7.7.48 sofosbuvir the enzyme (RdRp) of the SARS-CoV-2 RNA virus represents the most optimal target for an antiviral drug. Linear amino acid sequence as well as molecule structure show the highest homology to RdRps of other positive-sense RNA viruses. It is highly predictable that an antiviral developed for an RNA virus with a genome of the same polarity (i.e. sofosbuvir for HCV) could have a higher inhibitory efficacy against the SARS-CoV-2, compared to antiviral developed for negative-sense RNA viruses Severe acute respiratory syndrome coronavirus 2

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn Severe acute respiratory syndrome coronavirus 2
-
 diphosphate + RNAn+1
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
2.7.7.48 Severe acute respiratory syndrome coronavirus 2 P0DTD1 replicase polyprotein 1ab; SARS-CoV-2
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn
-
 Severe acute respiratory syndrome coronavirus 2 diphosphate + RNAn+1
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.7.7.48 RDRP
-
 Severe acute respiratory syndrome coronavirus 2
2.7.7.48 SARS-CoV-2 RNA polymerase
-
 Severe acute respiratory syndrome coronavirus 2

General Information

EC Number General Information Comment Organism
2.7.7.48 drug target the enzyme (RdRp) of the SARS-CoV-2 RNA virus represents the most optimal target for an antiviral drug. Linear amino acid sequence as well as molecule structure show the highest homology to RdRps of other positive-sense RNA viruses. It is highly predictable that an antiviral developed for an RNA virus with a genome of the same polarity (i.e. Sofosbuvir for Hepatitis C virus) could have a higher inhibitory efficacy against the SARS-CoV-2, compared to antiviral developed for negative-sense RNA viruses Severe acute respiratory syndrome coronavirus 2